Is there a role for maintenance rituximab in splenic marginal zone lymphoma?

Maintenance Rituximab in Splenic Marginal Zone Lymphoma

Maintenance rituximab following induction therapy can be considered in splenic marginal zone lymphoma (SMZL) as it improves progression-free survival and depth of response, though its role is less established than in follicular lymphoma.

Evidence-Based Recommendation

The 2020 ESMO guidelines for marginal zone lymphomas specifically address SMZL and state that maintenance rituximab (every 2 months for 1-2 years) may improve PFS 1. This represents the highest-quality guideline evidence directly addressing your question.

Key Supporting Data

Rituximab monotherapy as induction is highly effective in SMZL, achieving:

• Overall response rates >80-90% 1, 2
• Complete response rates of approximately 40-50% 1, 3
• 10-year PFS of 63% and OS of 85% 2

The maintenance benefit has been demonstrated in retrospective series showing:

• Improved complete response rates from 42% post-induction to 71% after maintenance 2
• 7-year PFS of 75% with maintenance versus 39% without (p<0.0004) 2, 3
• However, no overall survival benefit has been demonstrated 2

Clinical Algorithm for Decision-Making

Consider maintenance rituximab if:

1. Patient achieved partial response (not complete response) after induction rituximab
2. High-risk features present (elevated LDH, B symptoms, extensive bone marrow involvement)
3. Patient is young and fit with good performance status
4. Goal is to maximize depth and duration of response

Observation may be appropriate if:

1. Complete response (including molecular remission) achieved after induction
2. Low-risk disease (HPLLs/ABC score A) 4
3. Patient preference for less treatment exposure
4. Elderly patients with comorbidities where infection risk is concerning

Important Caveats

Maintenance is NOT standard of care - Unlike follicular lymphoma where rituximab maintenance has Level I, Grade A evidence 5, SMZL maintenance data comes from single-center retrospective studies, not randomized trials 2, 3.

The schedule differs from follicular lymphoma: SMZL maintenance is typically every 2 months for 1-2 years 1, whereas follicular lymphoma uses every 2-3 months for 2 years 5.

Rituximab remains effective at relapse 3, so deferring maintenance and retreating at progression is a reasonable alternative strategy.

Practical Considerations

The choice between immediate maintenance versus observation with retreatment at progression should weigh:

• Quality of initial response (PR favors maintenance; CR favors observation)
• Patient risk factors (high-risk features favor maintenance)
• Infection risk (late-onset neutropenia and hypogammaglobulinemia are concerns with prolonged rituximab exposure 6)
• Patient values regarding treatment burden versus disease control

Monitor during maintenance for: neutropenia, infections (especially respiratory), and hypogammaglobulinemia with IgG levels 6.